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Abstract
Background: Estimates of baseline incidence of childhood intussusception could help safety monitoring after the
introduction of rotavirus vaccines. We studied the incidence of intussusception in Uzbekistan, a GAVI-fund eligible
state in Central Asia.
Methods: We retrospectively reviewed intussusception cases in children <2 years of age treated during 2004-2008
at 15 hospitals in the Bukhara region of Uzbekistan. Demographic and clinical data as well as information on
diagnostic and treatment practices were obtained from hospital records. We categorized cases using the Brighton
collaboration clinical case definition and calculated the national incidence rate.
Results: Over a 5-year study period, 67 confirmed cases were identified, of which 67% were boys. The median age
was 12 months, and no seasonal trend in the distribution of cases was observed. The diagnostic methods used
included abdominal radiography (87%) and ultrasonography (57%). Intussusception reduction by air enema was
successful in 33 (49%) patients and 34 (50%) cases underwent surgery. A total of 4 deaths occurred, including 3
deaths in infants aged 0-6 months. The median length of hospital stay was 7.3 (range 0-37) days. The incidence of
intussusception is estimated at 23 (95% CI 13.6-32.4) cases per 100,000 child-years, corresponding to approximately
237 cases annually.
Conclusions: This is the first study to estimate the incidence of childhood intussusception prior to the
introduction of the rotavirus vaccination in Uzbekistan. A prospective surveillance system using a standardized case
definition is needed in order to better examine the occurrence of intussusception in developing countries.
Background
Intussusception (IS) is the most common cause of bowel
obstruction in young children, which involves an invagi-
nation of a proximal segment of the intestine into a dis-
tal segment. Intussusception is characterized by a
sudden onset of abdominal pain, vomiting, rectal bleed-
ing, and the presence of a palpable abdominal mass [1].
The condition is diagnosed by ultrasonography, radiol-
ogy or surgery, and is usually treated by using air or
hydrostatic reduction enema under radiologic or ultra-
sound guidance. However, surgery may be required in
some cases, and approximately 10% of patients with IS
undergo an intestinal resection due to a vascular injury
to the intestine [2]. Intussusception primarily affects
children, with the peak incidence reported at between 4
to 10 months of age [2], although adults cases are
reported as well [1]. The background incidence of IS
varies from 0-17.8 cases per 100,000 children [3-5] to
302 cases per 100,000 children [6,7] across various
regions, with a recently decreasing trend in IS incidence
reported in the industrialized countries [8]. Case-fatality
rates also vary widely by region, and deaths from IS are
more common in developing settings than in industria-
lized countries [9].
Although the full etiology of IS remains unclear [1,10],
adenovirus infection has been reportedly associated with
an increased risk of IS [11]. However, natural rotavirus
infection is not believed to be linked to this condition
[11], but an association of IS with an oral rhesus-based
tetravalent rotavirus vaccine is well documented [12].
This vaccine was licensed in the USA in 1998 and admi-
nistered to approximately 500,000 infants; the subse-
quent risk of IS was estimated to be one case per 10,000
vaccine recipients [13]. In view of this association, the
vaccine was withdrawn from the market by the
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(Rotarix
®, GSK) was licensed in Mexico [14] and in
2006, another vaccine (Rotateq
®, Merck) was approved
in US [15]. At present, both vaccines are used in routine
immunization in several high and low-income countries.
Clinical trials of these vaccines and early post-licensure
data [16,17] demonstrated no major risk of IS after vac-
cination (<1 case in 20,000 vaccines). Even so, the risk
o fal o w e rm a g n i t u d ec o u l dn o tb ee n t i r e l yr u l e do u t
before further post-licensure data are accumulated. For
that reason, local data on the baseline incidence and
epidemiology of IS are important for countries that are
considering using rotavirus vaccines to help with post-
introduction safety monitoring.
As in many other developing countries, such data are
not available in Uzbekistan, a GAVI-fund eligible coun-
try in Central Asia with 650,000 annual births [18]. It is
estimated that at least 30% of all hospitalizations for
acute gastroenteritis in Uzbek children <5 years of age
are attributable to rotavirus, and 1,174-1,857 rotavirus
deaths in children <5 years old occur annually [19]. In
case of rotavirus vaccine introduction in Uzbekistan,
monitoring IS as a part of the surveillance of vaccine-
associated adverse events would be challenging since no
IS surveillance is currently conducted. In addition, a
limited amount of previous reports do not allow for the
establishment of reliable baseline rates for IS among
children [20]. Therefore, our aim is to estimate the inci-
dence and describe the epidemiology of IS in young
children before vaccine introduction in order to assist
future safety monitoring. This study is based on meth-
ods described in the World Health Organization
(WHO) guidelines for the post-marketing surveillance of
rotavirus vaccine safety [21] and applies the internation-
ally standardized criteria for defining IS as per the
recommendations of the Brighton Collaborations Work-
ing Group [22].
Methods
Study area and participating hospitals
Uzbekistan is administratively divided into 12 regions,
and we selected the Bukhara region in the central part
of the country as the surveillance area for this study.
This region was chosen based on WHO guidelines
which recommended a surveillance area with a popula-
tion of at least 50,000 infants to establish IS incidence
with a 95% confidence interval of 1.0-3.7 per 10,000
population [23]. The region includes 11 districts and the
2 cities of Bukhara and Kagan; the total population of
the region was 1,561,338 in 2008 with 59,238 being chil-
dren <2 years of age (source: Ministry of Health). The
Uzbek health care system is state-owned and includes
outpatient clinics and hospital facilities at the local and
district levels, in addition to tertiary hospitals at the
regional level. Patients with IS are usually admitted and
managed in the surgical ward of district hospitals with a
majority of cases treated in the district they reside in.
Sometimes cases may be admitted to hospitals in other
districts within the same region or to regional hospitals.
In the Bukhara region, a total of 15 hospitals (11 district
hospitals, 2 hospitals in Bukhara, 1 hospital in Kagan,
and the Regional Center for Emergency Surgery in
Bukhara) diagnose and treat IS cases. In order to maxi-
mize the number of case findings, all 15 hospitals were
included in this study. Permission to use data in the
study was received from the participating hospitals.
Case definition and data sources
Children <24 months of age who were diagnosed with
IS at one of the 15 hospitals in the Bukhara region from
1 January 2004 through 31 December 2008 were eligible
for the study. Using the case definition developed by the
Brighton Collaboration Working Group [24], we classi-
fied all identified cases into confirmed, probable and
suspected, and used 3 levels of diagnostic certainty.
Patients at Level 1 of diagnostic certainty were defined
as confirmed cases. Level 1 requires one of the follow-
ing: demonstration of invagination of the intestine at
s u r g e r ya n d / o rb ye i t h e ra i ror liquid-contrast enema,
presence of intra-abdominal mass on ultrasonography,
and/or the demonstration of invagination at autopsy.
Cases diagnosed using a combination of clinical symp-
toms and signs according to Levels 2 and 3 of diagnostic
certainty were defined as probable. Suspected cases were
patients with a diagnosis of IS for whom the available
information did not allow for a determination of the
level of diagnostic certainty. Data for each identified
case were collected by reviewing admission and dis-
charge logs, case history records, ultrasonography, radi-
ology logs, and surgery reports from the respective
hospitals.
Data collection and analysis
For each identified child, we extracted information on
demographics, admission and discharge dates, clinical
signs and symptoms and their duration, as well as diag-
nostic and treatment procedures performed. Symptoms
and signs were recorded as positive or negative only if
the presence or absence of the symptom or sign was
documented by the medical and/or nursing staff in the
patient’s records. Data were summarized on the standar-
dized questionnaire, entered into an electronic database
and checked for accuracy, and the data extraction and
entry were performed by the same investigator. We ana-
lyzed the information according to age, sex, clinical
signs, year and month of hospitalization, and diagnostic
and treatment-related characteristics. Because early diag-
nosis and treatment of IS could provide better
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length of hospital stay for patients admitted <24 hours
and ≥24 hours after the onset of symptoms. The preva-
lence rate was calculated by using the following formula:
result of the ratio of number of intussusception to the
number of children under the age of 2 years for each
year in Bukhara region, followed by calculation of the
average prevalence rate for 5 years. Based on the census
data (source: Ministry of Health) and the prevalence of
IS in the Bukhara region the estimated number of IS for
whole Uzbekistan was calculated. A statistical analysis
was conducted by using STATA Version 10 (STATA-
Corp LP, College Station, Texas, USA). Categorical vari-
ables were compared by Mantel-Haenzel and Fisher’s
exact tests, and continuous variables were compared by
an analysis of variance or the Kruskal-Wallis test. All
statistical tests were two-tailed, and a P-value of <0.05
was considered significant. For this study the approval
of Ethics committee of Ministry of Health of Uzbekistan
and the Ethics committee for medical research in
Norway had received.
Results
During 5 years, 67 confirmed cases of IS in children <24
months of age were identified, corresponding to an inci-
dence of 23 cases [95% CI 13.6-32.4] per 100,000 child-
years or approximately 237 cases per year. A slightly
higher incidence among children 0-6 months of age that
will be targeted by rotavirus vaccination was observed
(Table 1). Among confirmed cases, boys (67%) were sig-
nificantly (p < 0.05) younger than girls (10.4 vs. 15.4
months), and the median age was 12.1 months. We
found a biphasic age distribution with the fist peak in
children aged 3-6 months and the second peak among
those 18 months and older (Figure 1).
The most frequent symptoms were abdominal pain
(97%), palpable intestinal mass (97%), and bile-stained
vomiting (80.6%). The lethargy (83.6%) and pallor
(64.2%) were also observed frequently. Detection of
blood on rectal examination (82.1%) and presence of IS
(79.1%) or fluid level and dilated loops on plain abdom-
inal radiography (20.9%) were the main symptoms for
diagnosis. A rectal mass was detected in 3 cases (4.5%),
and the presence of “red currant jelly” stool was only
r e p o r t e di nas i n g l ec a s e .T h ec l a s s i ct r i a do fv o m i t i n g ,
passage of blood through the rectum and abdominal
pain was documented in 8 (11.9%) of 67 children. The
clinical presentation at admission also included symp-
toms of concurrent gastroenteritis in 36% of children
and concurrent respiratory symptoms in 49% of cases.
We did not detect any significant differences in the dis-
tribution of symptoms by age or sex. No statistically sig-
nificant changes in the monthly occurrence of IS were
found despite a potential increase in the number of
cases during April and May (Figure 2). Importantly, no
increase was observed during autumn when most rota-
virus disease occurs in Uzbekistan [19].
The most frequent diagnostic methods were plain
abdominal radiography (86.6%) and ultrasonography
(56.7%); diagnosis was made at surgery in 5 cases (7.5%),
and in 2 cases, IS was first diagnosed clinically and later
confirmed at surgery. The frequency of using various
diagnostic procedures did not differ among the study
hospitals. A reduction of IS by air enema was attempted
in 60 patients, but was successful in only 33 (49.3%)
children. Thirty four (50.7%) cases underwent surgery,
of which seven patients did not have previous air
enema. These patients were admitted >24 hours after
symptoms onset and had features of intestinal vascular
Table 1 Incidence of intussusception-associated hospitalizations in children aged <24 months, Bukhara region,
Uzbekistan, 2004-2008
Age, months Boys Girls Total
n (%) Rate
a (95%CI) n (%) Rate
a (95%CI) n (%) Rate
a (95%CI)
0-6 19 (42.2) 46.1 (32.9-59.5) 4 (18.2) 9.7 (3.7-15.9) 23 (34.3) 27.9 (17.6-38.3)
7-12 9 (20.0) 27.3 (17.1-37.6) 3 (13.6) 9.1 (3.2-15.1) 12 (17.9) 18.2 (9.9-26.6)
13-18 9 (20.0) 25.2 (15.4-35.0) 6 (27.3) 16.8 (8.8-24.9) 15 (22.4) 21.0 (12.0-30.0)
19-24 8 (17.8) 22.4 (13.2-31.7) 9 (40.9) 25.2 (15.4-35) 17 (25.4) 23.8 (14.3-33.4)
Total 45 30.9 (20.0-41.8) 22 15.1 (7.5-22.8) 67 23.0 (13.6-32.4)
a Rates per 100,000 child-years.
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Figure 1 Age distribution of intussusception in 67 children
aged <24 months, Bukhara region, Uzbekistan, 2004-2008.
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blood per rectum or blood on rectal examination.
A reduction by air enema was used less often in
younger children, and surgery rates were more frequent
in children aged 0-6 months (60.9%) compared with
older children (45.5%). Overall, 4 deaths occurred
among the 67 patients which yielded a case-fatality rate
of 6% with a higher rate in infants aged 0-6 months
compared to older children (15% vs 2.3%). The mean
length of hospital stay was 7.3 days, but patients under-
going surgery stayed in the hospital 5 times longer (12.3
days) than patients with a successful reduction by air
enema (2.2 days) (p < 0.001). It is known that the earlier
a child arrives at the hospital after the onset of illness,
the higher the frequency of successful conservative
treatment [1]. In our study, air enema reduction was
more likely to be successful in patients presented within
12 hours following the onset of symptoms (a 72.7% suc-
cess rate), with no deaths reported in such cases. By
comparison, a reduction by air enema was successful in
only 59.6% of patients treated within 24 hours after
symptom onset, with a single death occurring in
this group. Among children admitted within the first
24 hours after the onset of illness, no intestinal resection
was performed. However, 4 of 9 children admitted >24
hours after symptom onset had intestinal resection, with
3 deaths in these patients compared to a single death in
children admitted earlier to the hospital.
Discussion
The withdrawal of the first rotavirus vaccine from the
market due to the increased risk of IS in vaccine recipi-
ents emphasized the need for a careful assessment of
the safety of new vaccines. Although available evidence
to date does not indicate the risk of IS after vaccination,
a vigilant post-marketing surveillance is recommended
to rule out such risk. The ability to assess a risk of a
rare adverse event will depend on the availability of
information concerning the background rates of the
event in the population of interest. Such data on IS are
limited in Central Asia, a region with a substantial diar-
rheal burden that could benefit from the introduction of
rotavirus vaccination [25,26]. Our study is the first to
document the incidence and epidemiology of childhood
IS in the most populous country in Central Asia, using
the internationally accepted case definition. Our esti-
mates of IS incidence at 23 cases per 100,000 children is
lower compared to rates reported from industrialized
countries, such as the United States (50 per 100,000)
[27], Australia (66 per 100,000) [28], and Europe (66-
224 per 100,000) [29]. But our estimates are higher than
figures from developing countries (18 cases per 100,000
in India and 0-17.8 per 100,000 in Bangladesh) [4], and
similar to the incidence reported in middle-income
Venezuela (24 per 100,000 children) [3]. However, com-
parisons of incidence rates for IS among different
regions should be careful as these rates may be affected
by variations in study methods, differences in genetic
and lifestyle factors, and health care practices. Our esti-
mates are based on the retrospective surveillance of
cases, not allowing detection of all cases, thus resulting
in the potential underestimation of incidence. Moreover,
we calculated national rates using data from a single
region, and if any differences in the incidence by region
were to exist within the country, it would not have been
reflected in our estimates.
Epidemiology of IS in Uzbekistan was similar to that
described in other parts of the world. Previous reports
specify that this condition is more frequent in males,
with our study yielding a male to female ratio of 2:1.
This ratio was reported to be varying widely across dif-
ferent regions, but all reports indicated predominance of
males. For example, in geographically close Asia region,
this ratio was reported to reach from 1.3:1 in Singapore
[30] to 9:1 in India [31,32]. Most cases of IS occurred in
infants between 3-6 months of age, which is the age
when rotavirus vaccination is administered. This may
challenge surveillance of intussusception following vacci-
nation as a possible increase in cases of intussusception
due to vaccination may coincide with its natural peak.
In Uzbekistan, no distinct seasonality of IS was detected,
which is similar to reports from countries in the Ameri-
cas [3,33] and Europe [34,35], In Uzbekistan, no distinct
seasonality of IS was detected, which is similar to
reports from countries in the Americas [3,33] and
Europe [34,35]. Due to a small number of observations,
we are unable to determine if a slight increase in the
number of cases in April and May is truly seasonal.
Among symptoms of IS among hospitalized children,
abdominal pain (97.0%) and the presence of an intestinal
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Figure 2 Monthly distribution of intussusception in children
aged <24 months, Bukhara region, Uzbekistan, 2004-2008.
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Page 4 of 6mass (97.0%) were most frequently reported. These
symptoms develop during the first hours of IS. However,
87% of hospitalized cases were lethargic and 82% had
blood detected during rectal examination, indicating a
more progressed IS. The majority of children (87%)
were hospitalized within 24 hours after symptom onset,
and given good access to emergency health care services
in Uzbekistan, most children would be hospitalized
promptly. However, the time required to diagnose IS is
highly dependent on clinicians’ skills and the availability
of the necessary equipment; so, a delayed diagnosis may
lead to a more progressed clinical presentation. In our
study, the most frequently used diagnostic method was
plain abdominal radiography, followed by ultrasonogra-
phy used in only a half of patients. Because all study
hospitals had ultrasound machines, it is possible that the
availability of personnel trained in transabdominal ultra-
sound techniques was limited, and physicians heavily
relied on clinical indications for diagnosis. Only 50% of
the cases in our study were managed successfully by air
enema, whereas the remaining cases had a failed radiolo-
gic reduction and were admitted 24 hours after symptom
onset. These patients needed surgical intervention, had a
longer hospital stay, and a higher case-fatality rate. This
is similar to reports from other countries that manage
pediatric patients with a longer duration of symptoms
[36]. Interestingly, no children in our study had repeated
enema reductions, though it is possible that some
patients may benefit from additional attempts. Among
children who survived surgery, no post-operative compli-
cations or recurrences of IS were reported. However one
died at surgery and two cases died immediately after
surgery.
Conclusions
In conclusion, our study provides useful information on
the incidence and epidemiology of childhood IS in
Uzbekistan. Because we did not conduct prospective
surveillance in the current study, additional research
using an active surveillance approach is needed to better
determine incidence rates. Such surveillance with a stan-
dard case definition will not only provide better infor-
mation for future post-marketing assessments on the
safety of rotavirus vaccines, but will also raise awareness
on IS among pediatricians and surgeons. More educa-
tion on diagnosis and management of IS in pediatric
population is needed in developing countries to help
improve rates of successful outcomes.
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